Please enable JS

FDA public Meeting Statement on Abuse Deterrent Opioid Formulations

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

FDA public Meeting Statement on Abuse Deterrent Opioid Formulations

Oct 30// Advocate Testimony Opioids

FDA public Meeting Statement on Abuse Deterrent Opioid Formulations 10-30-14

READ MORE

Idaho Board of Pharmacy Proposed Rule Testimony

Oct 22// Advocate Testimony

GHLF Idaho Board of Pharmacy Proposed Rule Testimony 10-22-14

READ MORE

Idaho Board of Pharmacy Testimony

Aug 08// Advocate Testimony

GHLF Idaho Board of Pharmacy Testimony 8-6-14

READ MORE

Indiana Health Finance Commission Biosimilars Testimony

Aug 08// Advocate Testimony Biosimilars

GHLF Indiana Health Finance Commission Biosimilars Testimony

READ MORE

Pennsylvania House Biosimilars Testimony

Aug 08// Advocate Testimony Biosimilars

GHLF Pennsylvania House Biosimilars Testimony

READ MORE

Seth’s 50 State Network Advocate Talking Points: Prior Authorization

Jun 09// Seth's 50 State Network Talking Points

1.      When a patient has to wait an extended period of time before beginning treatment, the patient, physician and public health suffers. 2.      The current system of prior authorization burdens the patient and physician leading to: a.       Delayed treatment and prolonged illness b.      Unstabilized care and the potential for permanent damage to occur c.       Diminished […]

READ MORE

Seth’s 50 State Network Advocate Brief: Prior Authorization

Jun 09// Memos Seth's 50 State Network

  How Can You Help?   Many states are currently introducing or revising legislation regarding prior authorization. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Prior Authorization message of poor outcomes, inefficiencies, and higher costs can be conveyed to:   State elected officials and staffers (legislators and […]

READ MORE

50 State Network Advocate Talking Points: Non-Preferred and Specialty Tier Drugs

Jun 09// Seth's 50 State Network Talking Points

1. As patients, our core concerns are to safeguard safety and the physician-patient relationship. 2. We believe only physicians should decide if a non-preferred or specialty tier drug is right for their patients. 3. Patients should pay the same for non-preferred drugs as they do for preferred drugs when it is the best or only […]

READ MORE

50 State Network Advocate Brief: Non-Preferred and Specialty Tier Drugs

Jun 09// Memos Seth's 50 State Network

How can you help? Help support bills that limit patients’ costs for specialty tier drugs. 87% of stand-alone Medicare Part D Prescription Drug Plans and 98% of Medicare Advantage-Prescription Drug Plans use specialty tiers, and this can be very expensive for those in need of special medicines. Patients who need non-preferred or specialty tier drugs […]

READ MORE

What is research and why should you care?

Apr 21// Memos

by Ben Nowell, MSW, Ph.D.   Anyone in science or academia will tell you that the primary goal of undertaking a Ph.D. is to learn how to become a research scientist. Having recently completed a Ph.D. myself, I now feel more excited, yet more daunted than ever about scientific research and its implications. But what […]

READ MORE